5 big analyst AI moves: Apple lifted to Buy, AI chip bets reassessed
Derek Maetzold, President and CEO of Castle Biosciences (NASDAQ:CSTL), sold 1,339 shares of common stock on October 20, 2025, at prices ranging from $22.290 to $22.615, realizing approximately $30,047. The transaction comes as Castle Biosciences, currently valued at $686 million, maintains strong financial health with an impressive 81% gross profit margin and robust liquidity position.
Following the transaction, Maetzold directly owns 62,988 shares of Castle Biosciences. Additionally, he has indirect ownership through various trusts, including The Maetzold Descendants 2020 Trust (52,923 shares), Derek Maetzold 2020 Irrevocable Trust (44,986 shares), and several Maetzold 2018 Remainder Trusts for the benefit of his children, each holding between 3,615 and 3,618 shares. Maetzold also has indirect ownership through DJM Grantor Retained Annuity Trusts No. 5, 6 and 7 holding 85,959, 18,718 and 44,323 shares respectively. According to InvestingPro, the company maintains excellent financial health with a current ratio of 6.85 and more cash than debt on its balance sheet.
In other recent news, Castle Biosciences reported its earnings for the second quarter of 2025, delivering a significant surprise to investors. The company achieved an earnings per share (EPS) of $0.15, which was a notable improvement over the anticipated loss of $0.51. Castle Biosciences’ revenue also exceeded expectations, reaching $86.2 million. This performance marks a positive development for the company as it continues to navigate the competitive landscape. These recent developments highlight the company’s ability to outperform market projections. Investors and analysts will likely keep a close watch on Castle Biosciences’ next moves following this earnings report.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.